Clinical Trial

BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)

Name: BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD) — clinical trial record (NCT07544160)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory inflammatory bowel disease.

Trial Details

NCT Number	NCT07544160
Lead Sponsor	iCell Gene Therapeutics Collaborators: iCAR Bio Therapeutics Ltd.
Conditions	Inflammatory Bowel Diseases (IBD)
Enrollment	18 participants
Start Date	2026-04-07
Primary Completion	2028-04-07 (estimated)
Study Completion	2028-04-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-22